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g.2012.0Abstract Uncoupling protein-2 (UCP2) regulates insulin secretion and may play an important role
in linking obesity to diabetes type 2 (T2D) that represents a major public health problem in Saudi
Arabia. The present study aimed to evaluate the association between the 45-bp insertion/deletion
(ins/del) in 30UTR exon 8 within the UCP2 gene as risk factors in T2D and obesity. This study
assessed the body mass index (BMI) in 113 Saudi subjects (46 T2D, 38 obese and 29 healthy con-
trols). The study genotyped for the UCP2 ins/del polymorphism using polymerase chain reaction,
evaluated its association with T2D and obesity, and compared its prevalence with those reported for
other ethnic populations. The genotype frequencies were 63% for the del/del genotype, 32% for the
ins/del genotype and 4% ins/ins genotype. The ANOVA between groups and within groups in T2D,
obese, and healthy controls is non-signiﬁcant (p> 0.05). The genotype distributions were ﬁgured
in-between compared to those ethnic populations reported in the literature. Based on this Saudi
study, the genetic variant UCP2 45-bp insertion/deletion do not inﬂuence T2D and obesity risks.
These results were similar, but the insertion allele was modest relative to other ethnic populations.
 2012 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.4065.
ri@kau.edu.sa
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4.0021. Introduction
Uncoupling proteins (UCPs) are mitochondrial membrane
transporters that disrupt the coupling between the mitochon-
drial proton gradient and ATP synthesis. UCP1 found in the in-
ner mitochondrial membrane of brown adipose tissue, serves as
a proton leak channel that allows cells to release stored energy
as heat. While the physiological role of UCP1 in thermogenesis
is relatively well understood, the function of its homologs,
UCP2 and UCP3, remains unclear. UCP2 is widely distributed
in human tissues (e.g. adipose tissue, skeletal muscle, heart,ier B.V. All rights reserved.
Table 1 Characteristics of phenotypic parameters: means of
age and body mass index (BMI) ± SD.
Parameter Age (years)
(mean + SD)
BMI (kg/m2)
(mean + SD)
Female/male
T2D 27–67 (51.14 ± 9.98) 18–30 (25.3 ± 2.6) 16/30
Obesity 20–67 (32.3 ± 10.0) 30–65 (36.2 ± 5.55) 14/24
Healthy
controls
20–66 (35.3 ± 9.0) 18–25 (23.02 ± 1.92) 10/19
258 E.H. Jiffriplacenta, liver, kidney, pancreas, and brain). It has been shown
that UCP2 plays neuromodulatory/neuroprotective roles in the
CNS, and UCP3 protects neurons from glucose-induced degen-
eration by preventing reactive oxygen species (ROS) formation
[1,2]. Indeed, superoxide or ROS production was increased in
macrophages, pancreatic islets, or skeletal muscle mitochondria
from UCP2-deﬁcient mice, respectively [3,4]. Suggested models
hypothesize roles for these genes in thermogenesis and body
weight regulation, the reduction of mitochondrial ROS produc-
tion, insulin regulation, and fatty acid export [5].
These recognized functions have justiﬁed the evaluation
of common variants in these genes for a role in a variety of
human diseases and phenotypes such as body composition
and resting energy expenditure [6], energy metabolism [7],
obesity [8,9], multiple sclerosis [10,11], diabetic neuropa-
thy [12,13], coronary artery disease [14], and schizophrenia
[15].
A genome scan performed at an average resolution of 8 cM,
the most relevant logarithm of the odds (LODs) score peak in
11q13, lies about 8 cM from the UCP2 gene locus [16]. Taken
together, it is apparent that the UCP2 gene is an excellent can-
didate for T2D. Many genetic polymorphisms have been iden-
tiﬁed in the UCP2 and UCP3 genes [17]. Of these, a 45-bp
insertion/deletion polymorphism (rs1800795) in the 30 untrans-
lated region (30UTR) of exon 8 in UCP2 has been studied in
association with various pathological phenotypes [18]. The
biological or functional relevance of both polymorphisms of
UCPs has been previously shown. The UCP2 45-bp inser-
tion/deletion polymorphism was reported to be related to
metabolic rate [19] and increased BMI [6,20,21], whereas the
UCP3 -55T allele was associated with increased expression of
UCP3 mRNA in the skeletal muscle [22]. However, the
patho-physiological impact of both polymorphisms remains
unknown.
Thus, the present study evaluated the polymorphism of 45-
bp insertion/deletion within the UCP2 gene as risk factors in
diabetes type 2 and obesity using a case-control analysis in
the Saudi population.Figure 1 Gel patterns of UCP2 45-bp insertion/deletion
polymorphism separated on 3% NuSieve gel. The homozygous
Ins/Ins showed one PCR fragment of size 457 bp, and Del/Del
showed a 412-bp fragment, while the heterozygous Ins/Del showed
two fragments (457 plus 412 bp). MW is a 50 bp ladder.2. Subjects and methods
2.1. Participants
Both cases and controls were of Saudi origin and resident in
the Western regions. For the sake of accuracy, we focused only
on those subjects for whom speciﬁc clinical information was
available. Cases were 113 selected from governmental and mil-
itary hospitals in Western regions of Saudi Arabia. Permission
to perform this study was obtained from the ethical committee
of the Faculty of Applied Medical Sciences, King Abdul-Aziz
University–Jeddah. Informed consents were taken from the
cases. The present study comprised three groups: 46 subjects
with T2D and 38 obese subjects. Patients with T2D were con-
secutively recruited who met the criteria of World Health
Organization [23]: (1) diabetes diagnosed after 25 years, (2)
insulin treatment not required for at least 2 years after diabetes
diagnosis, and (3) absence of clinically evident autoimmune
disease. We considered subjects as obese if their body mass in-
dexes were (BMI)P 30 kg/m2 according to American Obesity
Association [24]. In addition, age-matched healthy volunteers
consist of 29 subjects who were randomly selected. Selectioncriteria of control group were as follows: fasting plasma glu-
cose <6.1 mmol/L, no medications known to affect glucose
and lipid metabolism, and absence of systemic diseases. They
did not have a family history for T2D or obesity at ﬁrst degree
relative.
Patients, who were under certain medication (e.g. cortisone)
which could be the reason for their obesity, or could lead them
to diabetes, were excluded from the study at time of sampling.
In addition, patients who had endocrinal disorders that af-
fected their weights (e.g. Cushing disease, hypothyroidism)
and the female volunteers who had polycystic ovarian syn-
drome (PCOS) were also excluded. The average of ages and
BMI of T2D, and obese patients, besides the healthy control
group of the Saudi subjects ± standard deviations (SDs) are
shown in Table 1.
2.2. DNA isolation
Genomic DNA was extracted from blood lymphocytes using a
Spin Column miniKit (Qiagen, Valencia, CA).
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To amplify the 30UTR exon 8 deletion (del)/insertion (ins)
using polymerase chain reaction (PCR), genomic DNA
(200 ng) was added to a 15-ll reaction mixture containing
0.5 lM of each primer with 200 lM of each dNTP’s, 67 mM
Tris–HCl, 16 mM (NH4)2SO4, 0.01% Tween-20, 1 mMMgCl2,
and 0.45 U Taq DNA polymerase. Ampliﬁcation conditions
were 95 C for 5 min followed by 35 cycles of 95 C for 30 s,
65 C for 40 s, 72 C for 50 s. A ﬁnal extension of 72 C for
5 min was included.
Primer sequences were as forward, 50-CAG TGA GGG
AAG TGG GAG G-30 and reverse, 50-GGG GCA GGA
CGA AGA TTC-30 [19]. The ampliﬁed PCR product was
resolved on 3% NuSieve agarose, visualized and photographed
after staining with ethidium bromide using gel documentation
system (Bio imaging system, SynGene, USA). Ampliﬁcation of
the UCP2 del/ins resulted in 412-bp (Del) or 457-bp (Ins) frag-
ments (Fig. 1).2.4. Statistical analysis
Contingency tables were analyzed by Chi-square, continuous
variables by ANOVA and t-test was used to determine if there
is a difference between groups regarding the age and BMI
(SPSS for Windows, version 16.0).Figure 2 The body mass index (BMI), i
Table 2 Genotype determining risk of UCP2 45-bp insertion/deleti
Populations Total subjects Insertion/deletion genotypes n (%
Del/del (%) Ins/del (%)
Diabetic 46 29 (63.0) 15 (32.6)
Obese 38 24 (63.2) 12 (31.6)
Healthy control 29 19 (65.5) 10 (34.5)
a p-Values are considered as signiﬁcant if it is p< 0.05.3. Results
We studied the impact of the UCP2 45-bp ins/del genotypes on
prospective risk of T2D as well as the obesity among Saudi
families. In the present study, among the random sample
groups, the female/male gender ratio in T2D was 1:1.9, in
obese subjects was 1:1.7, and in healthy controls was 1:1.9.
The BMI reﬂected an informative shade on the Saudi sample
group of T2D and obesity. In T2D Saudi subjects, the BMI
frequency increased till reaching its maximum value at 24–29
and then decline at 30–31 kg/m2. The obese curve started at
a maximum BMI with 30–35 kg/m2 and then collapsed at
BMI with 56 and 65 kg/m2 (Fig. 2).
With regard to genotype frequency of the UCP2 45-bp ins/
del distribution in the present study, the ins/del was 32.6% in
T2D and 31.6% in obese subjects, while the frequencies of the
homozygous genotype ins/ins were 4.3% and 5.3% in T2D and
obese subjects, respectively. The most frequent genotype in all
Saudi sample groups, in this study, was the del/del genotype
ranging from 63% to 65.5%. Table 2 disclosed that the differ-
ences between the genotypes in separate T2D, obese and con-
trol groups were statistically highly signiﬁcant. The ANOVA
statistical parameters between groups and within groups in
T2D, obese, and healthy controls are shown in Table 3, with
no signiﬁcance (p> 0.05). As for the allele frequency of the
insertion allele, the results were 20.7%, 21.1%, and 17.2% in
T2D, obese subjects, and healthy controls, respectively.n the T2D and obese Saudi subjects.
on among obesity, T2D and obese Saudi subjects.
) v2 Value p-Valuea Insertion allele frequency
Ins/ins (%)
2 (4.3) 23.8 <0.0001 19/92 (0.21)
2 (5.3) 21.2 <0.0001 16/76 (0.21)
0 (0.0) 11.7 0.002 10/58 (0.17)
Table 3 ANOVA statistical testing for the T2D, and obese
Saudi sample group.
ANOVA Degree of
freedom (df)
F-test p-Value*
T2D group versus control 2 0.764 0.476
Obese group versus control 2 0.846 0.441
T2D versus obese groups 2 1.928 0.161
* p-Values are considered signiﬁcant if p< 0.05.
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Our diabetes mellitus is talented as a major public health trou-
ble in Saudi Arabia in parallel with the worldwide diabetes
pandemic, which is having a particular impact upon the Mid-
dle East and the third world [25,26]. This diabetes pandemic
description has accompanied the adoption of a modern life-
style and the abandonment of a traditional lifestyle, with a
resultant increase in rates of obesity and other chronic non-
communicable diseases. The indigenous Saudi population
seems to have a special genetic predisposition to develop
T2D that further ampliﬁed by a rise in obesity rates, a high
rate of consanguinity and the presence of other variables of
the insulin resistance syndrome [27].
Not surprisingly, the discovery of the UCP1 homologs
UCP2 [28] and UCP3 [29] in 1997 was warmly welcomed.
The ubiquitous expression of UCP2, the expression of UCP3
in skeletal muscle, and their homology with the ‘‘true’’ [30]
uncoupling protein UCP1 made UCP2 and UCP3 attractive
targets for interventions aimed at manipulating energy expen-
diture. Extensive research toward the regulation and the sup-
posed functions of these novel uncoupling proteins have
resulted in a vast amount of publications in the last decade
years [18].
Identiﬁcation of candidate gene responsible for obesity is an
impotent to understanding of molecular mechanisms not only
for obesity, but also for obesity-related conditions, such as
T2D. The discovery that UCP2 is present in pancreatic b-cells
and adipose tissues has led to the suggestion that such mole-
cules may be able to play an important role in etiology of obes-Table 4 The heterozygous and homozygous 45-bp insertion allele w
Population (references) Frequency (%) Total (n)
Ins/del Ins/ins
Obese Saudi Arabia 32 5 38
T2D Saudi Arabia (this study) 33 4 46
South Indians 28 5 453
British obese females [20] 42 5 83
Tongans [43] 3 0 1012
Obese French Cauc. 49 0 483
Control French Cauc. [42] 44 0 113
Germans [21] 40 7 815
Obese Danish Cauc. 39 11 744
Control Danish Cauc. [17] 42 9 872
T2D Japanese 20 3 99
Control Japanese [44] 32 5 120
American children [6] 37 7 89
Pima Native Americans [19] 35 16 790ity and T2D [31,32]. Many published papers have reported the
association between 866G>A SNP in the promoter region of
UCP2 with obesity and T2D [26,33–41].
Progressions have been achieved to clarify the important
role of the mitochondrial UCP2 gene, and the association be-
tween the two common polymorphisms; the 866G>A SNP
in the promoter region and 30UTR ins/del of exon 8 and
T2D, or obesity. Few studies have discussed the UCP2 45-bp
ins/del polymorphism, but studies on the role of polymor-
phism in UCP2 45-bp ins/del as a risk factor for T2D and
obesity have obtained controversial results [6,20,42,43].
There was a striking distribution of the UCP2 ins/del poly-
morphism in the Saudi population as previously indicated.
Table 4 compared the frequencies and observations of the
UCP2 30UTR exon 8 genotype in the present study with those
published for other ethnic populations. The allele frequency of
the insertion allele in T2D or obesity was 19/92 (21%) and of
the deletion allele was 73/92 (79%). Evaluation of the Saudi
frequency of the UCP2 insertion allele (21%) in either T2D
or obese subjects represented an intermediate magnitude with
other ethnic groups that report frequencies ranging from
13% in type 2 diabetic Japanese requiring insulin treatment
[44] to 33% in Pima Native Americans [19]. In this regard,
Fig. 3 displayed the two extremes for the UCP2 45-bp insertion
allele in both Tongans (a group of islands situated in the South
Paciﬁc), and Japanese [44]. Tongan and French populations
reported the absence of the ins/ins genotypes. Duarte et al.
[43] reported that the frequencies of the del/del and ins/del
genotypes were 97% and 3%, with the absence of ins/ins geno-
type. They concluded that there was a unique, near-uniform
distribution of the UCP2 45-bp ins/del polymorphism in Ton-
gans as a result of a founder effect and may be relevant to the
prevalence of obesity and T2D in Tonga. A French study of
obese and control subjects by Otabe et al. [42] found a del/
del frequency of 51% and 56% and ins/del of 49% and
44%, respectively, and no ins/ins genotype. Fig. 3 disclosed
that the pattern of the UCP2 30UTR ins/del genotypes in Saudi
subjects was near-consistent with that reported in South Indi-
ans [20]. Though there was an effect due to the small sample
size. This intermediacy might be due to the consequences of
much social intermarriage of ethnic Saudi families with some
Asians, and North Africa Arabs (Table 4).ithin the 30UTR–UCP2 gene in different ethnic populations.
Findings
No association with obesity or T2D
Association of ins/ins genotype with increasing BMI in
South Indians and decrease of leptin in obese British females
No association with obesity or T2D
No association with obesity or T2D
Association of ins-allele with obesity especially in elderly subjects
No association with obesity or T2D
No association with obesity or T2D
Association of ins/del with increasing BMI and increasing body fat
Association of ins/del with increasing SMR and decrease BMI
Figure 3 Comparison of the UCP2 45-bp insertion/deletion genotypes of T2D/obesity Saudi Arabia with different population.
UCP2 ins/del polymorphism in Saudi Arabia 261In conclusion, the present study found that the UCP2 45-bp
insertion/deletion polymorphism was not signiﬁcantly associ-
ated with T2D or obesity in Saudi subjects, but the insertion
allele is in a range of different ethnic populations. Our obser-
vations were in agreement with other previous reports, but sus-
tain the need for replication of a cohort study of the UCP2 45-
bp ins/del polymorphism among Type 2 diabetes and obesity.
It is also possible that one or more of these variants in conjunc-
tion with other variants increases risk for T2D and obesity.Acknowledgments
The author would like to express his deep appreciation to the
Research Deanship at King Abdulaziz University–Jeddah, for
the generous fund of the project (Grant #429/002-13).
He also would like to thank the families of diabetes and obes-
ity for their willing to share this study.
References
[1] Horvath TL, Diano S, Barnstable C. Mitochondrial uncoupling
protein 2 in the central nervous system: neuromodulator and
neuroprotector. Biochem Pharmacol 2003;65:1917–21.
[2] Vincent AM, Olzmann JA, Brownlee M, Sivitz WI, Russell JW.
Uncoupling proteins prevent glucose-induced neuronal oxidative
stress and programmed cell death. Diabetes 2004;53:726–34.
[3] Arsenijevic D, Onuma H, Pecqueur C, Raimbault S, Manning BS,
Miroux B, et al. Disruption of the uncoupling protein-2 gene in
mice reveals a role in immunity and reactive oxygen species
production. Nat Genet 2000;26:435–9.
[4] Krauss S, Zhang CY, Scorrano L, Dalgaard LT, St-Pierre J, Grey
ST, et al. Superoxide-mediated activation of uncoupling protein 2
causes pancreatic beta cell dysfunction. J Clin Invest
2003;112:1831–42.
[5] Krauss S, Zhang CY, Lowell BB. The mitochondrial uncoupling-
protein homologues. Nat Rev Mol Cell Biol 2005;6:248–61.
[6] Yanovski JA, Diament AL, Sovik KN, Nguen TT, Li H, Sebring
NG, et al. Associations between uncoupling protein 2, body
composition, and resting energy expenditure in lean and obeseAfrican American, white, and Asian children. Am J Clin Nutr
2000;71:1405–20.
[7] Kovacs P, Ma L, Hanson RL, Franks P, Stumvoll M, Bogardus
C, et al. Genetic variation in UCP2 (uncoupling protein-2) is
associated with energy metabolism in Pima Indians. Diabetologia
2005;48(11):2292–5.
[8] Liu YJ, Liu PY, Long J, Lu Y, Elze L, Recker RR, et al. Linkage
and association analyses of the UCP3 gene with obesity pheno-
types in Caucasian families. Physiol Genom 2005;22(2):197–
203.
[9] Ochoa MC, Santos JL, Azcona C, Moreno-Aliaga MJ, Martinez-
Gonzalez MA, Martinez JA, et al. Association between obesity
and insulin resistance with UCP2–UCP3 gene variants in Spanish
children and adolescents. Mol Genet Metab 2007;92(4):351–8.
[10] Otaegui D, Saenz A, Ruiz-Martinez J, Olaskoaga J, Lopez de
Munain A. UCP2 and mitochondrial haplogroups as a multiple
sclerosis risk factor. Mult Scler 2007;13(4):454–8.
[11] Vogler S, Goedde R, Miterski B, Gold R, Kroner A, Koczan D,
et al. Association of a common polymorphism in the promoter of
UCP2 with susceptibility to multiple sclerosis. J Mol Med
2005;83(10):806–11.
[12] G-Jr Rudofsky, Schroedter A, Schlotterer A, Voron’ko OE,
Schlimme M, Tafel J, et al. Functional polymorphisms of UCP2
and UCP3 are associated with a reduced prevalence of diabetic
neuropathy in patients with type 1 diabetes. Diabetes Care
2006;29(1):89–94.
[13] Yamasaki H, Sasaki H, Ogawa K, Shono T, Tamura S, Doi A,
et al. Uncoupling protein 2 promoter polymorphism 866G/A
affects peripheral nerve dysfunction in Japanese type 2 diabetic
patients. Diabetes Care 2006;29(4):888–94.
[14] Humphries SE, Cooper JA, Talmud PJ, Miller GJ. Candidate
gene genotypes, along with conventional risk factor assessment,
improve estimation of coronary heart disease risk in healthy UK
men. Clin Chem 2007;53(1):8–16.
[15] Yasuno K, Ando S, Misumi S, Makino S, Kulski JK, Muratake
T, et al. Synergistic association of mitochondrial uncoupling
protein (UCP) genes with schizophrenia. Am J Med Genet B
Neuropsychiatr Genet 2007;144(2):250–3.
[16] Ghosh S, Watanabe RM, Valle TT, Hauser ER, Magnuson VL,
Langefeld CD, et al. The Finland–United States Investigation of
Non-Insulin-Dependent Diabetes Mellitus Genetics (FUSION)
study I. An autosomal genome scan for genes that predispose to
type 2 diabetes. Am J Hum Genet 2000;67:1174–85.
262 E.H. Jiffri[17] SNP, Short genetic variations. <http://www.ncbi.nlm.nih.gov/
projects/SNP/>.
[18] Dalgaard LT, Sorensen TI, Andersen T, Hansen T, Pedersen O.
An untranslated insertion variant in the uncoupling protein 2 gene
is not related to body mass index and changes in body weight
during a 26-year follow-up in Danish Caucasian men. Diabeto-
logia 1999;42:1413–6.
[19] Walder K, Norman RA, Hanson RL, Schrauwen P, Neverova M,
Jenkinson CP, et al. Association between uncoupling protein
polymorphisms (UCP2–UCP3) and energy metabolism/obesity in
Pima indians. Hum Mol Genet 1998;7:1431–5.
[20] Cassell PG, Neverova M, Janmohamed S, Uwakwe N, Qureshi A,
McCarthy MI, et al. An uncoupling protein 2 gene variant is
associated with a raised body mass index but not Type II diabetes.
Diabetologia 1999;42:688–92.
[21] Evans D, Minouchehr S, Hagemann G, Mann WA, Wendt D,
Wolf A, et al. Frequency of and interaction between polymor-
phisms in the beta3-adrenergic receptor and in uncoupling
proteins 1 and 2 and obesity in Germans. Int J Obes Relat Metab
Disord 2000;24:1239–45.
[22] Schrauwen P, Xia J, Walder K, Snitker S, Ravussin E. A novel
polymorphism in the proximal UCP3 promoter region: effect on
skeletal muscle UCP3 mRNA expression and obesity in male
nondiabetic Pima Indians. Int J Obes Relat Metab Disord
1999;23:1242–5.
[23] The expert committee on the diagnosis and classiﬁcation of
diabetes mellitus: report of the expert committee on the diagnosis
and classiﬁcation of diabetes mellitus. Diabetes Care 21 (Suppl.
1);1998:S5–19.
[24] American Obesity Association; 2005. <www.obesity.org>.
[25] Elhadd TA, Al-Amoudi AA, Alzahrani AS. 2007 Epidemiology,
clinical and complications proﬁle of diabetes in Saudi Arabia: a
review. Ann Saudi Med 2007;27(4):241–50.
[26] Tayeb MT. Association of the UCP2 866G/A polymorphism
with type 2 diabetes and obesity in Saudi population. Egypt J Med
Hum Genet 2009;10(2):228–36.
[27] Alsmadi O, Al-Rubeaan K, Wakil SM, Imtiaz F, Mohamed G,
Al-Saud H, et al. Genetic study of Saudi diabetes (GSSD):
signiﬁcant association of the KCNJ11 E23K polymorphism with
type 2 diabetes. Diabetes Metab Res Rev 2008;24(2):137–40.
[28] Fleury C, Neverova M, Collins S, Raimbault S, Champigny O,
Levi-Meyrueis C, et al. Uncoupling protein-2: a novel gene linked
to obesity and hyperinsulinemia. Nat Genet 1997;15: 269–272.
[29] Boss O, Samec S, Paoloni-Giacobino A, Rossier C, Dulloo A,
Seydoux J, et al. Uncoupling protein-3: a new member of the
mitochondrial carrier family with tissue-speciﬁc expression. FEBS
Lett 1997;408:39–42.
[30] Nedergaard J, Matthias A, Golozoubova V, Jacobsson A,
Cannon B. UCP1: the original uncoupling protein––and perhaps
the only one? New perspectives on UCP1, UCP2, and UCP3 in the
light of the bioenergetics of the UCP1-ablated mice. J Bioenerg
Biomembr 1999;31:475–91.
[31] Chan CB, MacDonald PE, Saleh MC, Johns DC, Marba`n E,
Wheeler MB. Overexpression of uncoupling protein 2 inhibits
glucose-stimulated insulin secretion from rat islets. Diabetes
1999;48(7):1482–6.[32] Esterbauer H, Schneitler C, Oberkoﬂer H, Ebenbichler C,
Paulweber B, Sandhofer F, et al. A common polymorphism in
the promoter of UCP2 is associated with decreased risk of obesity
in middle-aged humans. Nat Genet 2001;28:178–83.
[33] Dalgaard LT, Pedersen O. Uncoupling proteins: functional
characteristics and role in the pathogenesis of obesity and type 2
diabetes. Diabetologia 2001;44:946–65.
[34] Krempler F, Esterbauer H, Weitgasser R, Ebenbichler C, Patsch
JR, Miller K, et al. A functional polymorphism in the promoter
of UCP2 enhances obesity risk but reduces type 2 diabetes risk in
obese middle-aged humans. Diabetes 2002;51:3331–5.
[35] Sesti G, Cardellini M, Marini MA, Frontoni S, D’Adamo M, Del
Guerra S, et al. A common polymorphism in the promoter of
UCP2 contributes to the variation in insulin secretion in glucose-
tolerant subjects. Diabetes 2003;52:1280–3.
[36] Ji Q, Ikegami H, Fujisawa T, Kawabata Y, Ono M, Nishino M,
et al. A common polymorphism of uncoupling protein 2 gene is
associated with hypertension. J Hypertens 2004;22:97–102.
[37] Sasahara M, Nishi M, Kawashima H, Ueda K, Sakagashira S,
Furuta H, et al. Uncoupling protein 2 promoter polymorphism
866G/A affects its expression in beta-cells and modulates clinical
proﬁles of Japanese type 2 diabetic patients. Diabetes
2004;53:482–5.
[38] Wang H, Chu WS, Lu T, Hasstedt SJ, Kern PA, Elbein SC.
Uncoupling protein-2 polymorphisms in type 2 diabetes, obesity,
and insulin secretion. Am J Physiol–Endocrinol Metab
2004;286:E1–7.
[39] Bulotta A, Ludovico O’Coco A, Di Paola R, Quattrone A, Carella
M, et al. The common 866G/A polymorphism in the promoter
region of the UCP-2 gene is associated with reduced risk of type 2
diabetes in Caucasians from Italy. J Clin Endocrinol Metab
2007;90:1176–80.
[40] Gable DR, Stephens JW, Cooper JA, Miller GJ, Humphries SE.
Variation in the UCP2–UCP3 gene cluster predicts the develop-
ment of type 2 diabetes in healthy middle-aged men. Diabetes
2006;55:1504–11.
[41] Shen H, Qi L, Tai ES, Chew SK, Tan CE, Ordovas JM.
Uncoupling Protein 2 promoter polymorphism 866G/A, central
adiposity, and metabolic syndrome in Asians. Obesity (Silver
Spring) 2006;14(4):656–61.
[42] Otabe S, Clement K, Rich N, Warden C, Pecqueur C, Neverova
M, et al. Mutation screening of the human UCP2 gene in
normoglycemic and NIDDM morbidly obese patients: lack of
association between new UCP2 polymorphisms and obesity in
French Caucasians. Diabetes 1998;47:840–2.
[43] Duarte NL, Colagiuri S, Palu T, Wang XL, Wilcken DEL. A
45-bp insertion/deletion polymorphism of uncoupling protein 2
in relation to obesity in Tongans. Obesity Res 2003;11(4):
512–7.
[44] Shiinoki T, Suehiro T, Ikeda Y, Inoue M, Nakamura T, Kumon
Y, et al. Screening for variants of the uncoupling protein 2 gene in
Japanese patients with non-insulin-dependent diabetes mellitus.
Metabolism 1999;48:581–4.
